Jun Xie

List of Publications by Year
in descending order

28 papers	1,355 citations	430874 18 h-index	526287 27 g-index
30 all docs	30 docs citations	30 times ranked	1842 citing authors

#	Article	IF	Citations
1	Long-term, efficient inhibition of microRNA function in mice using rAAV vectors. Nature Methods, 2012, 9, 403-409.	19.0	188
2	MicroRNA-regulated, Systemically Delivered rAAV9: A Step Closer to CNS-restricted Transgene Expression. Molecular Therapy, 2011, 19, 526-535.	8.2	143
3	MicroRNA 122, Regulated by GRLH2, Protects Livers of Mice andÂPatients From Ethanol-Induced Liver Disease. Gastroenterology, 2018, 154, 238-252.e7.	1.3	128
4	Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses. Science Translational Medicine, 2021, 13, .	12.4	99
5	Short DNA Hairpins Compromise Recombinant Adeno-Associated Virus Genome Homogeneity. Molecular Therapy, 2017, 25, 1363-1374.	8.2	74
6	Recombinant adenoâ€associated virusâ€“mediated inhibition of microRNAâ€21 protects mice against the lethal schistosome infection by repressing both ILâ€13 and transforming growth factor beta 1 pathways. Hepatology, 2015, 61, 2008-2017.	7.3	71
7	Bone-targeting AAV-mediated silencing of Schnurri-3 prevents bone loss in osteoporosis. Nature Communications, 2019, 10, 2958.	12.8	70
8	Adeno-associated Virus Genome Population Sequencing Achieves Full Vector Genome Resolution and Reveals Human-Vector Chimeras. Molecular Therapy - Methods and Clinical Development, 2018, 9, 130-141.	4.1	58
9	LATS suppresses mTORC1 activity to directly coordinate Hippo and mTORC1 pathways in growth control. Nature Cell Biology, 2020, 22, 246-256.	10.3	56
10	AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice. Nature, 2022, 604, 343-348.	27.8	44
11	A Rationally Engineered Capsid Variant of AAV9 for Systemic CNS-Directed and Peripheral Tissue-Detargeted Gene Delivery in Neonates. Molecular Therapy - Methods and Clinical Development, 2018, 9, 234-246.	4.1	42
12	Adeno-Associated Virus Neutralizing Antibodies in Large Animals and Their Impact on Brain Intraparenchymal Gene Transfer. Molecular Therapy - Methods and Clinical Development, 2018, 11, 65-72.	4.1	38
13	Comparative Analysis of the Capsid Structures of AAVrh.10, AAVrh.39, and AAV8. Journal of Virology, 2020, 94, .	3.4	38
14	Inhibition of miR-378a-3p by Inflammation Enhances IL-33 Levels: A Novel Mechanism of Alarmin Modulation in Ulcerative Colitis. Frontiers in Immunology, 2019, 10, 2449.	4.8	37
15	AAV-Genome Population Sequencing of Vectors Packaging CRISPR Components Reveals Design-Influenced Heterogeneity. Molecular Therapy - Methods and Clinical Development, 2020, 18, 639-651.	4.1	37
16	Down-regulation of microRNA-203-3p initiates type 2 pathology during schistosome infection via elevation of interleukin-33. PLoS Pathogens, 2018, 14, e1006957.	4.7	33
17	Bone-Targeting AAV-Mediated Gene Silencing in Osteoclasts for Osteoporosis Therapy. Molecular Therapy - Methods and Clinical Development, 2020, 17, 922-935.	4.1	32
18	Adeno-Associated Virus-Mediated MicroRNA Delivery and Therapeutics. Seminars in Liver Disease, 2015, 35, 081-088.	3.6	30

#	Article	IF	Citations
19	Adenine Base Editing In Vivo with a Single Adeno-Associated Virus Vector. , 2022, 1, 285-299.		27
20	Conditional, inducible gene silencing in dopamine neurons reveals a sex-specific role for Rit2 GTPase in acute cocaine response and striatal function. Neuropsychopharmacology, 2020, 45, 384-393.	5.4	26
21	Effective and Accurate Gene Silencing by a Recombinant AAV-Compatible MicroRNA Scaffold. Molecular Therapy, 2020, 28, 422-430.	8.2	20
22	MicroRNA-96 Promotes Schistosomiasis Hepatic Fibrosis in Mice by Suppressing Smad7. Molecular Therapy - Methods and Clinical Development, 2018, 11, 73-82.	4.1	18
23	Synergistic Deoxynucleoside and Gene Therapies for Thymidine Kinase 2 Deficiency. Annals of Neurology, 2021, 90, 640-652.	5.3	14
24	Regulation of sclerostin by the SIRT1 stabilization pathway in osteocytes. Cell Death and Differentiation, 2022, 29, 1625-1638.	11.2	12
25	Coagulation factor IX gene transfer to non-human primates using engineered AAV3 capsid and hepatic optimized expression cassette. Molecular Therapy - Methods and Clinical Development, 2021, 23, 98-107.	4.1	7
26	High-Throughput Quantification of In Vivo Adeno-Associated Virus Transduction with Barcoded Non-Coding RNAs. Human Gene Therapy, 2019, 30, 946-956.	2.7	6
27	Low-Dose Recombinant Adeno-Associated Virus-Mediated Inhibition of Vascular Endothelial Growth Factor Can Treat Neovascular Pathologies Without Inducing Retinal Vasculitis. Human Gene Therapy, 2021, 32, 649-666.	2.7	5
28	Serotype-dependent recombinant adeno-associated vector (AAV) infection of Epsteinâ€“Barr virus-positive B-cells, towards recombinant AAV-based therapy of focal EBVâ€‰+â€‰lymphoproliferative disorders. Virology Journal, 2021, 18, 223.	3.4	2